Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/24/30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/22/28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	1.05TCr 6.98TCr 933.71Cr 862.57Cr 781.68Cr 1.46TCr 99TCr 1.49TCr 10TCr 4.11TCr 52TCr 3.92TCr 3.84TCr 1,64000Cr	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	1.05TCr 7TCr 936.33Cr 864.99Cr 783.88Cr 1.47TCr 1LCr 1.49TCr 10TCr 4.12TCr 52TCr 3.94TCr 3.85TCr 1,64400Cr	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/24/30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/22/28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/21/26	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/20/17	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/20/07	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/20/30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/20/30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/20/14	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/19/25	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/19/25	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/19/13	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/19/12	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/19/31	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/21/02	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/20/17	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/20/29	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/20/27	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/20/27	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Share Price

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	164.41Cr
ELI LILLY AND COMPANY	-2.54%	+1.31%	+55.10%	+120.84%	1,16500Cr
JOHNSON & JOHNSON	-1.42%	+3.23%	+37.07%	+74.26%	64TCr
ABBVIE INC.	+0.16%	+0.08%	+25.14%	+97.36%	50TCr
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	38TCr
MERCK & CO., INC.	-1.34%	-0.47%	+66.63%	+40.56%	36TCr
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	30TCr
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	27TCr
AMGEN INC.	-1.79%	+1.57%	+49.97%	+60.87%	24TCr
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.24%	+101.19%	19TCr
Average	-0.60%	+1.94%	+36.91%	+70.90%	40.57TCr
Weighted average by Cap.	-0.25%	+2.67%	+41.08%	+82.28%

	2017	2018
Net sales	3.02Cr 20Cr 2.69Cr 2.49Cr 2.26Cr 4.22Cr 286.37Cr 4.29Cr 30Cr 12Cr 150.04Cr 11Cr 11Cr 473.04Cr	3.95Cr 26Cr 3.53Cr 3.26Cr 2.95Cr 5.52Cr 374.91Cr 5.62Cr 39Cr 16Cr 196.43Cr 15Cr 15Cr 619.29Cr
Net income	-95.42L -6.37Cr -85.21L -78.72L -71.34L -1.33Cr -91Cr -1.36Cr -9.47Cr -3.75Cr -47Cr -3.58Cr -3.5Cr -149.62Cr	-52.85L -3.53Cr -47.2L -43.6L -39.51L -73.92L -50Cr -75.14L -5.25Cr -2.08Cr -26Cr -1.98Cr -1.94Cr -83Cr
Net Debt	1.81Cr 12Cr 1.61Cr 1.49Cr 1.35Cr 2.52Cr 171.37Cr 2.57Cr 18Cr 7.09Cr 90Cr 6.77Cr 6.63Cr 283.07Cr	2.94Cr 20Cr 2.62Cr 2.42Cr 2.2Cr 4.11Cr 278.95Cr 4.18Cr 29Cr 12Cr 146.15Cr 11Cr 11Cr 460.77Cr